SEC Tracker
Get the app

Zymeworks ZYME

Zymeworks partners with Roche on DLL3-targeting therapy

Item 1.01 Enters material agreement, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Zymeworks granted Roche exclusive rights to ZW209
  2. Roche to pay $55M upfront and up to $718M in milestones
  3. Zymeworks retains ownership of Zymeworks Platform IP
  4. Roche to handle development, manufacturing, and commercialization

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Zymeworks files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Anaptysbio ANAB public float $633M, Dec 31, 2025
  2. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  3. ImmunityBio IBRX public float $690M, Jun 30, 2025
  4. Evoke Pharma EVOK
  5. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.